Why Halozyme Therapeutics, Inc. (HALO) stock moved
Halozyme Therapeutics, Inc. (HALO) shares tumbled 15.7% to $103.63 as of November 7, 2026, a sharp decline from the prior close of $122.96. BestStocks flagged the session as a major change for HALO. Below, we break down what changed for HALO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
HALO fell 15.7% to $103.63
HALO tumbled 15.7% in its latest session, moving from $122.96 to $103.63.
What it means for Halozyme Therapeutics, Inc. investors
For Halozyme Therapeutics, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Halozyme Therapeutics, Inc. (HALO) moved +13.94% from $90.50 to $103.12 on 2026-08-07, reaching a new 30-day high. Weighing against that: Material negative event; Sharp 15.7% decline — elevated risk. Wall Street's consensus price target sits at $110.00, implying +6.1% upside from $103.63. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality medium (73/100). With earnings roughly 101 days out, the next report is the most likely near-term test of the move.
HALO price reaction
HALO last traded at $103.63, down $19.33 (-15.72%) from the previous close of $122.96. The session traded on 2.8× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $103.63 and $131.18, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Halozyme Therapeutics, Inc. (HALO)
The consensus analyst price target on Halozyme Therapeutics, Inc. (HALO) is $110.00, 6.1% above the recent $103.63. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 1 downgrade. Here is how the bullish and bearish cases on HALO line up.
The bullish case
- Wall Street's consensus price target of $110.00 implies +6.1% upside from $103.63.
- The Street's most bullish target is $130.00 (+25.4%).
- Halozyme Therapeutics, Inc. (HALO) moved +13.94% from $90.50 to $103.12 on 2026-08-07, reaching a new 30-day high.
The bearish case
- The most bearish analyst target is $90.00 (-13.2%).
- 1 analyst downgrade in the past 90 days, most recently Leerink Partners to Market Perform (2026-11-06).
- Material negative event.
- Sharp 15.7% decline — elevated risk.
- High volume 2.8x on decline — distribution signal.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 7, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for HALO
In-depth HALO event analyses
Frequently asked questions about HALO
Why did Halozyme Therapeutics, Inc. (HALO) stock move?
HALO tumbled 15.7% to $103.63. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did HALO stock fall?
HALO lost 15.72% ($19.33) versus the prior close of $122.96, last trading at $103.63 on 2.8× average volume.
When is Halozyme Therapeutics, Inc.'s next earnings date?
HALO's next earnings report is estimated for 2027-02-16 — about 101 days away.
What is the analyst price target for HALO?
The consensus analyst price target for HALO is $110.00, about 6.1% above the current $103.63. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 1 downgrade.
How BestStocks tracks HALO
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared HALO-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for HALO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 7, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.